Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Novavax's interest expense for the
three
months ended in Mar. 2026 was CHF -3.9 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was CHF-17.4 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Novavax's Operating Income for the
three
months ended in Mar. 2026 was CHF -12.1 Mil. Novavax's Interest Expense for the
three
months ended in Mar. 2026 was CHF -3.9 Mil.
Novavax did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Novavax (XSWX:NVAX) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Novavax's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as
Novavax did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Warning Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Novavax Incs earnings cannot cover its interest expense. If the situation continues, the company may have to issue more debt.
Novavax Interest Expense Historical Data
* Premium members only.
The historical data trend for Novavax's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-17.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Expense of CHF-17.4 Mil mean?
Novavax (XSWX:NVAX) has a Interest Expense of CHF-17.4 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Novavax and its competitors.
Is Novavax's Interest Expense too high?
Novavax's current Interest Expense is CHF-17.4 Mil. Overall, Novavax has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Novavax's Interest Expense compare to MPLT and COAG?
Novavax's Interest Expense of CHF-17.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Novavax and its competitors. Novavax's current Interest Expense is CHF-17.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Novavax (XSWX:NVAX) has a current Interest Expense of CHF-17.4 Mil. The stock's GF Value™ is CHF3.14, compared to a current price of CHF7.61 — trading 142.4% above its estimated fair value. The current Interest Expense is CHF-17.4 Mil. Novavax's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Novavax (XSWX:NVAX), the current Interest Expense is CHF-17.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novavax (XSWX:NVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Novavax stock appears to be overvalued.
The current stock price of CHF7.61 is trading 142.4% above its estimated GF Value™ of CHF3.14.
Key valuation signals for XSWX:NVAX:
Interest Expense: CHF-17.4 Mil
GF Value™: CHF3.14 vs. price of CHF7.61 (142.4% above fair value)
No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
50GF Score
Get the complete analysis for XSWX:NVAX
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:NVAX has been successfully added to your 
